HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 532Generated: October 28, 2026
1-(2-Chloropyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carbaldehyde → 1-(2-(3-chloro-1,2-dimethyl-1H-indol-5-ylamino)pyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carbaldehyde
https://huagongshe.com/reaction/532
Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | 1-(2-Chloropyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carbaldehyde | HCID 73012315 | — |
| Reactant | 3-Chloro-1,2-dimethyl-1H-indol-5-amine | HCID 89708648 | — |
| Reagent | Potassium Carbonate | HCID 11430 | — |
| Catalyst | Palladium (II) acetate | HCID 4144353 | — |
| Catalyst | 2-Dicyclohexylphosphino-2',4',6'-triisoprophylbiphenyl | HCID 11155794 | — |
| Solvent | 1,4-Dioxane | HCID 31275 | — |
| Product | 1-(2-(3-chloro-1,2-dimethyl-1H-indol-5-ylamino)pyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carbaldehyde | HCID 86698988 | 64.6% |
Reaction Steps
A 40 mL scintillation vial charged with 3-chloro-1,2-dimethyl-1H-indol-5-amine (192 mg, 0.99 mmol), 1-(2-chloropyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carbaldehyde (200mg, 0.90 mmol), palladium(II) acetate (10.08 mg, 0.04 mmol), dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine (x--phos) (42.8 mg, 0.09 mmol) and Dioxane (8mL) After being degassed by nitrogen bubbling , the reaction mixture was heated 100 °C for 6 hours. At this stage most of the starting material was consumed. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with water and brine. The organic layer separated, dried over sodium sulfate, filtered and concentrated. The crude material was purified by silica gel chromatography (Isco, Hexane/ethyl acetate, 0-100%, 25 minutes) to give 1-(2-((3-chloro-1,2-dimethyl-1H-indol-5-yl)amino)pyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carbaldehyde (221 mg, 64.6 %) as a yellow solid. LC/MS (2 minute, Acid _CV10.olp method) 381 (M + 1), 1.27 minutes.
Provenance & Evidence
| Source dataset | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-e7d99d2977b74881941c52721ae6fed1 |
|---|
| Source note | 750 AstraZeneca ELN dataset |
|---|